[Comparison of surgical and radioactive synovectomy in various disorders of the knee joint]. / Porovnanie chirurgickej a rádioaktívnej synovialektómie pri rôznych afekciách kolenného klbu.

The authors evaluate after an interval of 1-20 years the long-term results of surgical synovectomy in 454 patients and radioactive synoviorthesis in 528 patients performed at the First Orthopaedic Clinic, Medical Faculty, Comenius University and Faculty Hospital in Bratislava and at the Orthopaedic and Traumatological Clinic of the Medical Faculty in Martin in 1969-1991. The most frequent diagnosis in surgical synovectomy is rheumatic synovitis in radioactive synovectomy arthrotic synovitis (47.6% and 68.6%). The authors evaluate both methods of synovectomy according to Aidem-Baker and compare the results of the two methods. They found significantly more very good and good results after surgical synovectomy (54.8% and 33.5%) as compared with radioactive synoviorthesis (15.5% and 38.0%). Conversely they found significantly more satisfactory and poor results in radioactive synoviorthesis (29.1% and 17.4%) than after surgical synovectomy (8.8% and 2.9%) which comprise patients relatively satisfied with this procedure and who do not agree with other procedures.

[Advantages of the new radiopharmaceutic agent, 99mTC-mercaptoacetyltriglycine (99mTc-MAG3), in the diagnosis of kidneydiseases. A comparative study with 131I-OIH, 99mTc-DTPA and 99mTc-DMSA]. / Prednosti nového rádiofarmaka 99mTc-merkaptoacetyltriglycínu (99mTc-MAG3) v diagnostike ochorení obliciek. Porovnávacia stúdia s 131I-OIH, 99mTc-DTPA a 99mTc-DMSA.

The properties of 99mTc-mercaptoacetyltriglycine (MAG3), a new radiopharmaceutic for dynamic renal scintigraphy, were assessed in a series of 138 patients with different diseases of the uropoietic system. The physiological values of renographic curves were determined as well as the characteristics of MAG3 excretion, which closely resembled the values for 131I-OIH. On comparing the values of separate MAG3 clearance with standard radiopharmaceutics in 26 subjects examined, very good correlation coefficients (r) were obtained: 0.98, 0.96, and 0.92 for 131I-OIH, 99mTc-DMSA, and 99mTc-DTPA, respectively. Global MAG3 clearance reached 0.64 of the OIH value. The higher quality of scinfigraphic imaging than seen with the substances used so far, the favorable pharmacokinetic properties and the low radiation load (H(E) = 0.51 mSv in adults) of MAG3 determine the indication spheres in which it can best be used to advantage. Of the radiopharmaceutics used to date, MAG3 yields the best results. It can well substitute 123I-OIH, which is not readily available in our conditions, and can thus be expected to be widely used in clinical practice.

A new approach in radionuclide imaging to ureteric peristalsis using 99Tcm-MAG 3 and condensed images.

A new method for the evaluation of ureteric peristalsis is described. Standard, dynamic renal scintigraphy was carried out using 99Tcm-MAG 3 in 59 patients. Time-activity curves and condensed images over the ureter area were created simultaneously. A six-grade scale (O-V) was chosen for the classification of ureteral function. The results obtained were compared with parameters of renographic curves and other clinical findings. In a group of 13 patients, two different renal radiopharmaceuticals were used: 131I-OIH and 99Tcm-DTPA. The results show that the new method is suitable for the assessment of ureteral disorders, and has some advantages compared with previously described methods. 99Tcm-MAG 3, with a better target-to-background ratio compared to 131I-OIH and 99Tcm-DTPA, is the most suitable radiopharmaceutical for this purpose.

[Clinical evaluation of a new radiopharmaceutical agent 99mTc-mercaptoacetyltriglycine (MAG3)]. / Klinické hodnotenie nového rádiofarmaka 99mTc-merkaptoacetyltriglycínu (MAG3).

In the present clinically oriented study the authors checked the properties of 99mTc-mercaptoacetyltriglycine (MAG3), the new radiopharmaceutical for dynamic scintigraphy of the kidneys, in a group of 30 patients. They positively value particularly the high quality of visualization of the parenchyma and the urinary tract, the pharmacokinetic properties similar to those of 131I-orthoiodhippurate and the capability of representation of the kidneys with their markedly decreased function. They examined the take-up of the pharmaceutical in the liver, which is slightly more marked with the worsening tubular function and partly depends also on the length of the time interval between the preparation and administration of MAG3. No significant changes were found in the clinical and principal laboratory parameters after its administration. In conclusion, the authors point out to advantageous properties of the novel radiopharmaceutical for clinical use in our conditions.

[Mercaptoacetyltriglycine (MAG 3) 99mTc--a new radiopharmaceutic for uropoietic diagnoses]. / Merkaptoacetyltriglycín (MAG 3) 99mTc--nové rádiofarmakum v diagnostike uropoetického systému.

The present authors show mercaptoacetyltrigylcine (MAG 3), labelled with 99mTc technetium, as a novel prospective diagnostic agent of the uropoietic system, replacing the injections of sodium iodohippurate labelled with 131I. The paper reports the procedure of labelling of this novel radiopharmaceutical with technetium 99mTc, evaluation of its quality by chromatographic methods, and biological distribution of MAG 3 in laboratory animals in comparison with the biodistribution of injections of sodium iodohippurate labelled with 131I.

[The significance of a new radiopharmaceutic agent, 99mTc-mercaptoacetyltriglycine (MAG 3), in the diagnosis of diseases of the kidneys and urinary tract in children]. / Význam nového rádiofarmaka 99mTc-merkaptoacetyltriglycínu (MAG 3) v diagnostike ochorení obliciek a mocových ciest u detí.

Using the method of dynamic scintigraphy of the kidneys by means of a new radiopharmaceutical preparation, 99mTc--mercaptoacetyltriglicide [MAG 3], the authors examined 35 children with various urological and nephrological diseases. In indicated cases the examination was supplemented by administration of a diuretic, further projections or indirect mictional cystography. The authors assessed normal parameters of functional curves and their normal extent in a group of 18 healthy kidneys. They did not find a significant difference, as compared with results obtained by means of 131I-OIH. The assessed values of global clearance attained 66% of the 131I-OIH clearance values. In 60% of the patients the visualization of the parenchyma and in 80% the visualization of the efferent urinary pathways was better than when 99mTc-DTPA was used. In all instances the scintigrams were better than when 131I-OIH was used. The new radiopharmaceutical preparation combines the advantages of technetium-labelled preparations and the favourable pharmacokinetic properties of hippuran. It is suitable for quantification of tubular secretion. It is superior to hitherto used substances as regard the quality of visualization and in particular the lower radiation load. Therefore it is particularly suited for paediatric practice.

[Magistral preparation of methylene diphosphonate and its clinical evaluation in radionuclide diagnosis of the skeleton]. / Magistraliter pripravený metyléndifosfonát (MDP) a jeho klinické hodnotenie v rádionuklidovej diagnostike skeletu.

The present authors report on their own method of preparation of a frozen kit of methylenediphosphonate (MDP) which has been hitherto imported from the foreign currency area. The preparation after labelling with 99mTc serves for scintigraphy of the skeleton. The rate of MDP and the reducing reagent (SnCl2.2H2O)-5:1 proved to be the most advantageous. The preparation was compared with two more radiopharmaceuticals: hydroxyethylidenedisphosphanate (HEDP) and pyrophosphate (PYP). The results of a subjective evaluation of readability of scintigrams with grades 1-5 are unequivocally more favourable for MDP and HEDP (2.3 and 2.4) against PYP (3.1). MDP possessed the best rate of the number of impulses from the bone and the surrounding tissue--the background of the radiopharmaceuticals under study. The authors also examined the rapidity of uptake of MDP in the bone, kidney and its elimination from the plasma. The obtained results were in good agreement with commercial preparations tested at different laboratories. The use of MDP prepared in this manner is a contribution both to economy and clinical practice.